ProCE Banner Activity


Critical Actions in Emergency Medicine: Timely Diagnosis and Treatment of CAR-T and Bispecific Antibody–Related AEs in Multiple Myeloma


This webcast aims to provide healthcare professionals with information on how to properly diagnose and treat adverse events associated with immunotherapies for multiple myeloma.

Physician Assistants/Physician Associates: 1.25 AAPA Category 1 CME credits

Nurses: 1.25 Nursing contact hours

Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Pharmacists: 1.25 contact hours (0.125 CEUs)

Released: March 01, 2024

Expiration: February 28, 2025



Shonali Midha

Shonali Midha, MD

Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Instructor, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This program is intended for emergency medicine physicians, nurses, pharmacists, advanced practice providers in emergency medicine, and emergency medicine health professionals involved in the screening and management of patients with multiple myeloma who present to the emergency department for care.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Distinguish the different mechanisms of action for the BCMA-directed agents and their impact on T-cell function in patients with heavily pretreated relapsed or refractory multiple myeloma

  • Compare and contrast emerging safety and efficacy data on CAR T-cell therapies and bispecific T-cell engager antibodies for the treatment of patients with heavily pretreated relapsed or refractory multiple myeloma

  • Effectively identify and employ clinical and pharmacologic treatments for adverse events associated with the use of CAR T-cell therapy and bispecific T-cell engager antibodies approved for heavily pretreated relapsed or refractory multiple myeloma


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shonali Midha, MD

Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Instructor, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Shonali Midha, MD: consultant/advisor/speaker: Pfizer; individual publicly traded stocks and stock options: AbbVie.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP as noted below.​

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, CTI/SOBI, Daiichi Sankyo, Lilly, Morphosys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 01, 2024, through February 28, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.25 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-069-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days. 

Physician Associate Continuing Medical Education

Clinical Care Option, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credit. Approval is valid until  February 28, 2025. PAs should only claim credit commensurate with the extent of their participation.